Propanc Biopharma (PPCB) Other Non Operating Income (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Other Non Operating Income of -$19497.0 for Q4 2025, down 243.56% year-over-year from $13581.0 in Q4 2024, and up 1.06% quarter-over-quarter from -$19706.0 in Q3 2025.
Propanc Biopharma (PPCB) Other Non Operating Income (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Other Non Operating Income for 16 consecutive years, with -$19497.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income fell 243.56% year-over-year to -$19497.0; the TTM figure through Dec 2025 stood at -$52748.0 (down 197.05% YoY), while the FY2025 annual figure was -$89243.0, down 504.18% from the prior year.
- Other Non Operating Income climbed to -$19497.0 in Q4 2025 per PPCB's latest filing, from -$19706.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $165365.0 in Q1 2022 and bottomed at -$110215.0 in Q4 2021.
- Historically, Other Non Operating Income has averaged $10451.5 across 5 years, with a median of -$3504.5 in 2023.
- Annual changes were most pronounced in 2021 — Other Non Operating Income tumbled 343.65% — and 2022, when it soared 2267.77%.
- Propanc Biopharma's Other Non Operating Income stood at -$110215.0 in 2021, then surged by 87.31% to -$13988.0 in 2022, then jumped by 87.34% to -$1771.0 in 2023, then jumped by 866.85% to $13581.0 in 2024, then plunged by 243.56% to -$19497.0 in 2025.
- Business Quant data shows PPCB's Other Non Operating Income at -$19497.0 in Q4 2025, -$19706.0 in Q3 2025, and -$1059.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19,497.00 |
| Sep 30, 2025 | -19,706.00 |
| Jun 30, 2025 | -1,059.00 |
| Mar 31, 2025 | -12,486.00 |
| Dec 31, 2024 | 13,581.00 |
| Sep 30, 2024 | 52,787.00 |
| Jun 30, 2024 | -5,238.00 |
| Mar 31, 2024 | -6,781.00 |
| Dec 31, 2023 | -1,771.00 |
| Sep 30, 2023 | -15,948.00 |
| Jun 30, 2023 | 11,334.00 |
| Mar 31, 2023 | -19,025.00 |
| Dec 31, 2022 | -13,988.00 |
| Sep 30, 2022 | 65,173.00 |
| Jun 30, 2022 | -40,003.00 |
| Mar 31, 2022 | 165,365.00 |
| Dec 31, 2021 | -110,215.00 |
| Sep 30, 2021 | 109,129.00 |
| Jun 30, 2021 | 50,394.00 |
| Mar 31, 2021 | 6,984.00 |